Given this, to predict the mechanisms of acquired resistance which may emerge in patients with FGFR2-dependent gastric cancer following treatment with selective FGFR inhibitors, we generated three SNU-16 cell lines resistant (SNU-16R) to AZD4547, BGJ398, and PD173074, respectively. This evidence concerns the gene FGFR2 and gastric cancer.